1771912195
FLASCO OncoPod

Advertise on podcast: FLASCO OncoPod

Rating
★★★★★
5
from
2 reviews
This podcast has
37 episodes
Language
English
Date created
2024/10/02
Latest episode
2026/11/04
Average duration
19 min.
Release period
14 days

Description

The FLASCO OncoPod is a podcast series that brings you engaging interviews and conversations with oncology champions and thought leaders. Each episode explores important topics in cancer care, from the latest clinical advancements to FLASCO events and initiatives. Whether it’s discussing groundbreaking research, policy updates, or sharing personal stories from members, the OncoPod keeps oncology professionals informed and connected. It’s your go-to source for staying up-to-date on FLASCO’s efforts to support and strengthen the oncology community across Florida.

Unlock FLASCO OncoPod podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from FLASCO OncoPod podcast


Empowering the Next Generation of Oncology: SOFLOH & the Fellows and Residents Training Program
2026/11/04
Join FLASCO OncoPod for a special conversation with Dr. Jani and Dr. Rosas as they highlight the South Florida Fellows Hematology Oncology (SOFLOH) initiative and the upcoming FLASCO Fellows & Residents Training Program. In this episode, our guests discuss the importance of mentorship, professional development, and meaningful connections for the next generation of hematology and oncology professionals. Learn more about SOFLOH's mission to support fellows and residents, the opportunities available through FLASCO, and what attendees can look forward to at this year's training program. Whether you're a current fellow, resident, or physician passionate about supporting the future of oncology, this episode offers a closer look at the people and programs helping shape the next generation of cancer care.
The Nuance in mTNBC | Part 3: Toxicity, Delivery, and the Rest of the Journey
2026/11/04
Selecting an effective treatment is only the beginning of managing metastatic triple-negative breast cancer (mTNBC). In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk examine the practical challenges of delivering and sustaining therapy, from treatment initiation through disease progression. Using a longitudinal patient case and findings from a FLASCO clinician survey, faculty discuss toxicity prevention and management, dose modifications, and the clinical considerations surrounding antibody-drug conjugate (ADC) therapy. The conversation explores treatment scheduling, insurance authorization, financial barriers, and strategies to support treatment continuity. Faculty also address rebiopsy, biomarker reassessment, therapeutic sequencing, and the importance of timely clinical trial referrals to help optimize care throughout the patient's treatment journey. This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.
The Nuance in mTNBC | Part 2: The Patient the Trial Did Not Enroll
2026/10/28
How should clinicians approach metastatic triple-negative breast cancer (mTNBC) when a patient's treatment history does not align with the populations studied in clinical trials? In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk explore the challenges of managing patients who experience recurrence following neoadjuvant immunotherapy and chemotherapy. Through case-based discussion and insights from a FLASCO clinician survey, faculty examine the significance of treatment-free intervals, prior immunotherapy exposure, germline BRCA mutations, and the evolving first-line treatment landscape. The conversation also addresses the limitations of available clinical evidence, considerations for immunotherapy rechallenge, and individualized treatment strategies for patients with comorbidities, reduced performance status, or preferences that may limit therapeutic options. This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.
The Nuance in mTNBC | Part 1: Where the Answers Split
2026/10/20
Treatment decisions in metastatic triple-negative breast cancer (mTNBC) are becoming increasingly complex as new therapeutic options reshape the first-line landscape. In this episode of The Nuance in mTNBC, Dr. Edgardo Santos and Dr. Victoria Rizk examine the clinical decisions surrounding PD-L1 expression, germline BRCA mutations, and the evolving role of antibody-drug conjugates (ADCs). Drawing on insights from a FLASCO clinician survey, the discussion explores biomarker testing, treatment selection while results are pending, and the implications of recent first-line sacituzumab govitecan approvals. Faculty review findings from the ASCENT-03 and ASCENT-04 trials, address areas of clinical uncertainty, and discuss how emerging evidence influences shared decision-making when overall survival data remain immature. This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Sponsor, Gilead Sciences, Inc.
Drew Piers on Advocacy, Storytelling & Shaping the Future of Cancer Care
2026/08/03
In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing cancer care beyond the clinic. Drawing on years of experience working alongside healthcare organizations and oncology professionals, Drew discusses how trusted clinician voices can influence public policy, improve patient access to care, and strengthen public confidence in the healthcare system. Listeners will gain practical insights into communicating complex healthcare issues with clarity, combining patient stories with evidence-based data, and engaging policymakers in meaningful ways that drive positive change. Whether through community outreach, media engagement, or legislative advocacy, this episode highlights how every oncology professional can help shape the future of cancer care through authentic, patient-centered communication. Sachs Health INFLUENCE INDEX: https://sachsmedia.com/wp-content/uploads/2026/05/SachsHEALTH-Influence-Index-2026.pdf
The Evolving Management of Hepatocellular Carcinoma: Prevention, Multidisciplinary Care, and Emerging Therapies
2026/07/27
Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver disease and cancer management. In this episode of the FLASCO OncoPod, Dr. Beau Bosko Toskich, MD, FSIR, Professor of Radiology, Medical Oncology, and Radiation Oncology and Director of Interventional Oncology at Mayo Clinic Comprehensive Cancer Center, provides a comprehensive overview of the modern HCC treatment landscape. Dr. Toskich discusses the changing epidemiology of hepatocellular carcinoma, emphasizing the growing impact of metabolic-associated liver disease, the importance of early detection and surveillance, and opportunities for disease prevention. He explores how multidisciplinary collaboration—including hepatology, surgery, interventional radiology, medical oncology, and radiation oncology—has transformed patient care, while highlighting the expanding role of locoregional therapies, immunotherapy, transplant evaluation, and emerging combination treatment strategies. Listeners will gain practical insights into patient selection, downstaging approaches, and the latest advances that are reshaping outcomes for patients with HCC. Whether you routinely manage liver cancer or simply want to stay current on one of oncology's fastest-evolving disease states, this episode offers valuable clinical perspectives on delivering personalized, multidisciplinary care for patients with hepatocellular carcinoma.
The Evolving Role of Community Oncology: Delivering Academic-Level Cancer Care Close to Home
2026/07/20
In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the evolving role of community oncology and how today's practices are delivering academic-level cancer care closer to home. Together, they explore how community oncology has transformed over the past decade, highlighting advances in precision medicine, immunotherapy, clinical research, and innovative care models. The conversation examines how large practice networks maintain consistent, high-quality care while expanding access to cutting-edge therapies and clinical trials for patients across diverse communities. From scaling innovation across a statewide network to bringing academic-level expertise closer to home, this episode offers valuable insights into the future of oncology care and the increasingly vital role community oncology plays in advancing cancer treatment, research, and patient outcomes.
Part 4, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
2026/07/20
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection. In part 4, the panel examines the real-world barriers that continue to affect IHC testing, including variability in reflex testing, pathology workflows, tissue stewardship, and reporting consistency. Experts share practical strategies for improving communication between oncologists and pathologists, streamlining testing protocols, and ensuring patients receive timely, comprehensive biomarker evaluation. Looking ahead, the discussion explores how artificial intelligence, digital pathology, electronic medical record integration, and automated clinical trial matching may transform precision oncology while reinforcing that multidisciplinary collaboration remains essential to delivering high-quality, personalized cancer care. The episode concludes with key takeaways clinicians can implement to strengthen biomarker-driven decision-making in their own practices. This podcast is being sponsored by Daiichi Sankyo.
Part 3, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
2026/07/16
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection. The panel discusses how expanding biomarker indications are changing when and how testing is performed, from first-line diagnosis through disease progression. Experts explore the growing clinical importance of HER2-low and HER2-ultralow expression in breast cancer, the role of comprehensive biomarker testing in gynecologic malignancies, and how IHC and next-generation sequencing work together to guide personalized treatment strategies in thoracic oncology. The conversation also highlights the importance of standardized pathology reporting, multidisciplinary collaboration, and balancing timely treatment with the need for complete biomarker results to ensure patients receive the most appropriate targeted therapies. This podcast is being sponsored by Daiichi Sankyo.
Part 2, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
2026/07/16
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection. In part 2, the panel explores why routine biomarker testing is becoming an essential part of cancer care, highlighting how markers such as mismatch repair (MMR), HER2, PD-L1, and Claudin 18.2 are helping clinicians personalize treatment strategies and improve patient outcomes. Through real-world clinical examples, the discussion examines the value of reflex testing, when repeat testing may be appropriate, and how close collaboration between oncologists, pathologists, and multidisciplinary care teams helps ensure patients receive timely, biomarker-driven treatment. The conversation also addresses practical workflow considerations, including pathology communication, turnaround times, and strategies for integrating evolving testing standards into everyday clinical practice. This podcast is being sponsored by Daiichi Sankyo.
Part 1, Advancing Biomarker-Driven Care Through Optimized IHC Testing: Practical Insights on IHC Testing Across Tumor Types
2026/07/13
In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection. The conversation highlights how IHC is shaping clinical decision-making across breast, gastrointestinal, gynecologic, and thoracic cancers, with experts discussing reflex testing, tissue stewardship, workflow between pathology and oncology, and the growing importance of predictive biomarkers such as HER2, PD-L1, mismatch repair (MMR), Claudin 18.2, and hormone receptors. Panelists also share practical insights on when IHC provides the greatest clinical value, how testing protocols have adapted alongside emerging therapies, and why strong communication between clinicians and pathologists is essential for delivering timely, personalized cancer care. This podcast is being sponsored by Daiichi Sankyo.
CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors
2026/06/05
The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO OncoPod, FLASCO President Edgardo Santos, MD, FACP, FASCO, sits down with renowned CLL expert Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center to discuss how advances in targeted therapies are reshaping treatment decisions across the CLL continuum. Together, they explore the evolution of CLL care from chemoimmunotherapy to modern treatment approaches centered around BTK inhibitors, BCL2 inhibitors, and anti-CD20 monoclonal antibodies. The conversation examines how molecular and genetic risk factors, including IGHV mutation status, TP53 abnormalities, and cytogenetic findings, influence first-line treatment selection and long-term management strategies. Dr. Pinilla-Ibarz shares practical insights into the ongoing debate between fixed-duration combination regimens and continuous therapy approaches, highlighting the benefits, limitations, and patient-specific considerations that guide real-world clinical decision-making. The discussion also covers measurable residual disease (MRD), emerging MRD-guided treatment strategies, management of high-risk disease, sequencing therapies after relapse, and the growing role of next-generation BTK inhibitors. Looking ahead, the episode explores promising therapies on the horizon, including novel BTK degraders, next-generation BCL2 inhibitors, cellular therapies, and other innovative approaches that may further improve outcomes for patients living with CLL. Whether you are a hematologist, oncologist, advanced practice provider, or healthcare professional interested in the latest developments in blood cancers, this episode offers a comprehensive and clinically relevant update on where CLL treatment stands today and where the field is headed next.
What's New in Endometrial Cancer: Key Takeaways From SGO 2026
2026/06/02
Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting. In this episode, Dr. Jordan reviews promising new therapies, including emerging antibody-drug conjugates and novel hormonal treatment combinations, highlights exciting clinical trial results, and discusses long-term follow-up data from the practice-changing RUBY trial. From breakthrough research to upcoming Phase III studies that may shape the future standard of care, this conversation provides oncology professionals with key insights into the rapidly evolving treatment landscape for advanced and recurrent endometrial cancer.
ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia
2026/05/11
What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care? In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, advocacy, and the launch of ASCO Edge, a new educational resource designed to help oncology professionals better understand the operational and business side of cancer care. Dr. Zon reflects on her professional journey from community oncology practice to serving as President of ASCO, sharing how early experiences shaped her passion for empowering clinicians with the tools needed to manage practices, navigate evolving healthcare systems, and advocate for both patients and providers. Together, they explore: • The inspiration behind ASCO Edge • Why business education matters in oncology • Challenges facing modern cancer care delivery • How oncology professionals can strengthen operational knowledge • The importance of state societies and collaborative advocacy • What clinicians, pharmacists, APPs, fellows, and practice leaders can gain from the platform Designed by oncology professionals for oncology professionals, ASCO Edge offers practical, on-demand learning modules focused on real-world scenarios impacting cancer care today. Learn more about FLASCO and upcoming educational initiatives at FLASCO.org Get started with ASCO Edge today at https://www.asco.org/meetings-education/training-programs/asco-edge #FLASCO #Oncology #ASCO #CancerCare #CommunityOncology #HealthcareLeadership #MedicalEducation #OncoPod #OncologyPodcast #PracticeManagement #CancerResearch #OncologyProfessionals
"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls
2026/05/01
In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients. Building on the diagnostic and acute management discussions from earlier segments, the panel explores key considerations that guide care beyond the initial presentation. Topics include the role of genetic and complement testing, how to interpret mutation findings, and the factors that influence decisions around the duration of complement inhibition therapy. Through real-world insights, the discussion highlights the complexity of identifying underlying triggers, including drug exposure and infection, and the importance of clinical judgment when determining whether and when treatment can be safely discontinued. The panel also addresses practical challenges, from variability in testing access to navigating uncertainty in cases without clear pathogenic mutations. Listen as the experts walk through how thoughtful, individualized decision-making can support recovery, preserve renal function, and optimize long-term outcomes for patients with aHUS.

Podcast reviews

Read FLASCO OncoPod podcast reviews


5 out of 5
2 reviews

Podcast sponsorship advertising

Start advertising on FLASCO OncoPod relevant audience podcasts


What do you want to promote?